Michael Reader

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index505citations32works5.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(11), Synthesis and biological activity(9), Fibroblast Growth Factor Research(5), Kruppel-like factors research(5), Cyclopropane Reaction Mechanisms(4)

Publications32 total

Correction to “Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)”
Journal of Medicinal Chemistry·2025
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
Journal of Medicinal Chemistry·2024· 10 citedOpen Access
Data from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Methods from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Methods, Figures 1-4, Tables 1-2 from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Supplementary Tables 1-6 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Data from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Supplementary Figures 1-7 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Data from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Supplementary Tables 1-6 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Data from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Methods, Figures 1-4, Tables 1-2 from Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
2023Open Access
Supplementary Methods from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Supplementary Figures 1-7 from ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
2023Open Access
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Journal of Medicinal Chemistry·2021· 17 citedOpen Access
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Molecular Cancer Therapeutics·2021· 32 citedOpen Access
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 <i>H</i> ,2 <i>H</i> ,3 <i>H</i> -pyrrolo[3,2- <i>b</i> ]pyridin-1-yl)-2-[(2 <i>R</i> ,5 <i>R</i> )-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)
Journal of Medicinal Chemistry·2018· 51 citedOpen Access
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Journal of Medicinal Chemistry·2018· 63 citedOpen Access
Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP)
Journal of Medicinal Chemistry·2017· 70 citedOpen Access
ChemInform Abstract: The Synthesis of 3,3‐Dimethyl Aza‐ and Diazaindolines Using a Palladium‐Catalyzed Intramolecular Reductive Cyclization.
ChemInform·2016
page 1 of 2Next →

Frequent Co-authors

Sharna J. Rich(23), Nicola E. Wilsher(18), Valério Berdini(18), David C. Rees(17), Neil T. Thompson(16), Alison J.‐A. Woolford(13), Sandra Muench(13), Nicola G. Wallis(13), Tom D. Heightman(12), Joanne M. Munck(12), Alpesh Shah(12), Aurélie Courtin(11), Charlotte East(11), John F. Lyons(11), Marc O’Reilly(11), Caroline J. Richardson(11), Christopher W. Murray(11), Luke Bevan(10), Justyna Kucia-Tran(10), James E. H. Day(9)